Compare Amphastar Pharmaceuticals Inc (AMPH) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Standard Lithium Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Standard Lithium Ltd trades at $2.45 (market cap $624.94M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| AMPH | SLI | |
|---|---|---|
Market Cap | $863.95M | $624.94M |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $5.65 |
52-Week Low | $16.87 | $1.93 |
Enterprise Value | $1.26B | $484.14M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Standard Lithium (SLI) trades at $2.37, up 4.41% with a bullish technical signal despite mixed earnings performance. The company maintains 100% analyst buy ratings and strong institutional interest, including Amundi's 64.9% stake increase. Recent developments show progress toward final investment decision for the South West Arkansas lithium project, supported by a $225M DOE grant and key construction contracts. Financials reflect development-stage challenges with negative profitability metrics but substantial financing activity.
Outlook remains constructive as SLI transitions toward production with major project de-risking, though execution risks and negative cash flows warrant monitoring. The stock presents growth potential in lithium sector expansion but faces operational and funding challenges during development phase. Current valuation at 1.72x book value reflects market optimism about project economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
